Objective To explore the relationship between CD146(MCAM),microvessel density(MVD)in renal cell carcinoma(RCC) and its clinic-pathology,and to explore their correlation with clinic-pathologic parameter of RCC. Methods Immunohistochemisty was employed to determine the expression of CD146 and MVD in 43 RCC tissues and 20 normal control renal tissues. Results The positive expression of CD146 in RCC(90.7 ％,39/43) was remarkably higher than that in normal renal tissue(30.0 ％,6/20)(x2=27.77,P＜0.05).The expression of CD146 was not correlated with the category of RCC (x2=1.37,all P ＞0.05),but had a significant correlation to(the tumor volume x2=7.57)clinical stage(r=0.62) and metastasis of RCC(x2=19.99,P＜0.05). The MVD of RCC [(78.00±23.10)/200HP]was significantly higher than that of normal renal tissue [(23.05±7.93)/200HP].The MVD of CD146 was not correlated with the tumor volume and category of RCC (t=1.33,t=1.46,au P＞ 0.05),but had a significant correlation to clinical stage and metastasis of RCC (t=2.37,t=2.10,P＜ 0.05). There was a positive correlation between expression of CD146 and MVD in RCC(r=0.74,P＜0.05). Conclusion The overexpression of CD146 in RCC has a significant relation with tumor angiogenesis.The expression of CD146 and angiogenesis might serve as an important indicator of the development, progress and metastasis of RCC.

Objective To compare different Nrf2 expressions in glioblastoma cell lines and glioma stem cells (GSCs) from xenografts and to study the concentration of Nrf2 in nuclear. Methods GSCs were analyzed by immunofluorescence and different expressions of Nrf2 in glioblastoma cell lines and GSCs from xenografts were detected with real-time RCR and Western. Results GSCs were successfully isolated from xenografts of U251 and U87 cell lines. The percentage of tumor stem cells in total cells was 1.24%, and that was 1.63% in xenografts. Immunofluorescence indicated that Nrf2 was overexpressed in GSCs as compared with that in glioblastoma cell lines. Conclusion Nrf2 may be a potential biomarker and rational therapeutic target for GSCs.